The Company notes that results based on investigator-initiated use of its assets are also being presented.
'We are greatly encouraged by the progress of our clinical and preclinical programs,' said
[212Pb]VMT-NET for the Treatment of Neuroendocrine Tumors
The abstract describing Perspective's trial in progress of the Phase 1/2a dose escalation study (NCT05636618) in patients with unresectable or metastatic somatostatin receptor type 2 ('SSTR2')-positive neuroendocrine tumors ('NETs') who have not received prior peptide receptor radionuclide therapies ('PRRT') stated the trial's status as of
Perspective, in collaborating independent investigators, is evaluating dosimetry and the applicability of patient-specific dosing as determined by a target renal absorbed dose for [212Pb]VMT-NET. An abstract reported pooled data from ten patients recruited in the Company's sponsored Phase 0 imaging study and an investigator sponsored absorbed dose escalation study. The investigator reported [212Pb]VMT-NET was prescribed to three patients at individualized doses of 5.3, 7.9, and 13.3 mCi (cumulatively, delivered over two cycles) while targeting renal absorbed dose of 3.5Gy. Higher levels of targeted renal absorbed doses are in the protocol for subsequent cohorts of the investigator sponsored study.
The Company has been informed that updated results from the investigator initiated trial of [212Pb]VMT-NET in
Preclinical Progress on Targeted Therapies for Melanoma and Tumor Environments
The Company will present preclinical data for [212Pb]VMT01, a targeted -particle radionuclide therapy (-TRT) targeting the melanocortin 1 receptor ('MC1R'), used in combination with immune checkpoint inhibitors ('ICIs') in diverse murine melanoma models with high (B16-F10), mid (YUMM-D3) and low (YUMMwt) expressions of MC1R. These data provide a rationale for advancing the combination of [212Pb]VMT01 and ICIs to clinical investigations. The ongoing Phase 1/2a study of [212Pb]VMT01 is being amended to evaluate the safety and tolerability of Perspective's [212Pb]VMT01 in combination with the ICI nivolumab in patients with histologically confirmed melanoma and MC1R-positive imaging scans.
The final presentation will introduce [203/212Pb]-PSV-359, a novel cyclic peptide developed to target fibroblast activation protein alpha ('FAP'), a protein abundantly expressed by cancer-associated fibroblasts in tumor lesions and involved in promoting disease progression. [203/212Pb]-PSV-359 has a proprietary targeting moiety designed by Perspective to optimize 'theranostic' applications, representing a promising avenue for addressing FAP expressing cancers regardless of disease site.
About
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'estimate,' 'believe,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the Company's expectation that its clinical and preclinical programs will continue to progress; the Company's belief that it will showcase its activities with VMT-Net and other promising therapies at the
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the potential that regulatory authorities may not grant or may delay approval for the Company's product candidates; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; pre-clinical and early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of regulatory authorities may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company's ability to obtain and maintain regulatory approval for the Company's product candidates; delays, interruptions or failures in the manufacture and supply of the Company's product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its clinical development programs; the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of its product candidates; the ability of the Company to manage growth and successfully integrate its businesses; the Company's ability to maintain its key employees; sufficient training and use of the Company's products and product candidates; the market acceptance and recognition of the Company's products and product candidates; the Company's ability to maintain and enforce its intellectual property rights; the Company's ability to maintain its therapeutic isotope supply agreement with the
Contact:
Email: ir@perspectivetherapeutics.com
Email: PerspectiveIR@russopr.com
(C) 2024 Electronic News Publishing, source